Evidence map›Paper›PMID 41993483›Full record

ArticlebioRxiv : the preprint server for biology2026

Antimony 3: Extending human-readable model definitions for SBML Level 3 Core and Packages.

Adel Heydarabadipour, Lucian Smith, Joseph L Hellerstein, Herbert M Sauro

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Adel HeydarabadipourDepartment of Bioengineering, University of Washington, Seattle, Washington, United States of America.ORCID 0009-0009-2865-6128
Lucian SmithDepartment of Bioengineering, University of Washington, Seattle, Washington, United States of America.ORCID 0000-0001-7002-6386
Joseph L HellersteinDepartment of Bioengineering, University of Washington, Seattle, Washington, United States of America.ORCID 0000-0003-0802-4069
Herbert M SauroDepartment of Bioengineering, University of Washington, Seattle, Washington, United States of America.ORCID 0000-0002-3659-6817

Funding

TR&D3: Standards and Tools for Simulator Composition and Credibility portalP41EB023912 · NIBIB · UNIVERSITY OF WASHINGTON · PI HERBERT M. SAURO · 2018 to 2026
$11.4M
NIBIB NIH HHS P41 EB023912
6 · The paper itself

Abstract

Antimony is a human-readable language for defining and sharing models developed by the systems biology community. It enables scientists to describe biochemical networks with a simple syntax, while supporting seamless conversion to and from the Systems Biology Markup Language (SBML) community standard. Since Antimony's original release, both SBML and modeling practices have evolved significantly, creating a need to update Antimony to maintain its standards compliance and practical relevance. In this paper, we introduce Antimony 3, a comprehensive update that formalizes its cumulative improvements and extends its support for SBML Level 3 Core and Flux Balance Constraints (FBC), Distributions, Layout, and Render packages. Antimony 3 enables model specifications that combine kinetic reactions with flux balance analysis, represent uncertainty using probability distributions, add biological context through annotations, and define publication-ready visualizations, all within a unified plain-text format. Antimony 3 is delivered as a lightweight C/C++ library with a stable C API. It is available through official bindings for Python, Julia, and JavaScript/WebAssembly, as well as a cross-platform desktop GUI, which enables straightforward use across scripting environments, desktop applications, and browser-based tools. Antimony 3 is released as open-source software under the BSD 3-Clause License and is available at https://github.com/sys-bio/antimony.

Identifiers

PMID41993483
PMCPMC13082115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.